NeOnc Technologies Holdings 宣布,其针对复发性 IDH1 突变型高级别胶质瘤患者开发的鼻内给药产品 Neo100,在 2a 期临床试验中取得了积极的顶线数据。这一结果无疑为攻克这一难治性脑瘤带来了新的希望,并进一步验证了该公司在肿瘤精准治疗领域的创新实力。
NeOnc Technologies Holdings 宣布,其针对复发性 IDH1 突变型高级别胶质瘤患者开发的鼻内给药产品 Neo100,在 2a 期临床试验中取得了积极的顶线数据。这一结果无疑为攻克这一难治性脑瘤带来了新的希望,并进一步验证了该公司在肿瘤精准治疗领域的创新实力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.